MaxCyte Inc. Common Stock (MXCT)
Stock · NASDAQ · Health Care
$1.3as of 10/16/2026
Price chart
Active signals
MXCT Signal Track Record
How signals performed across all stocks →What MXCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -5.0% | 38% | June 25, 2026 |
| Bollinger Band Breakdown | 25 | -0.6% | 48% | October 1, 2026 |
| Bollinger Band Breakout | 22 | -3.0% | 41% | August 13, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.1% | 46% | October 1, 2026 |
| Any 20-session window (baseline) | -2.2% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GT…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 91
- Website
- www.maxcyte.com/
Fundamentals
- 1-day range
- $1.26$1.31
- Market cap
- $118.91M
- P/E (trailing)
- —
- P/E (forward)
- -5.30
- EPS (trailing)
- $-0.33
- Dividend yield
- —
- Beta
- 1.54
- Avg. volume
- 776.9K
How MaxCyte Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
MaxCyte Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MXCTMaxCyte Inc. Common Stock$1.3▲ 0.00%Market cap $118.91MP/E —$0.643$1.87
- ONMDOneMedNet Corp Class A Common Stock$4.51▼ 5.05%Market cap $37.18MP/E —$4.9$42.2
- BIAFbioAffinity Technologies Inc. Common Stock$3.73▼ 5.81%Market cap $4.12MP/E —$4.56$80.7
- ISPCiSpecimen Inc. Common Stock$0.917▼ 10.97%Market cap $3.35MP/E —$1.02$36.32
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MXCT MaxCyte Inc. Common Stock | $118.91M | — | $1.3 | ▲ 0.00% | $0.643$1.87 |
| ONMD OneMedNet Corp Class A Common Stock | $37.18M | — | $4.51 | ▼ 5.05% | $4.9$42.2 |
| BIAF bioAffinity Technologies Inc. Common Stock | $4.12M | — | $3.73 | ▼ 5.81% | $4.56$80.7 |
| ISPC iSpecimen Inc. Common Stock | $3.35M | — | $0.917 | ▼ 10.97% | $1.02$36.32 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- MaxCyte 13D Filing Shows Liontrust Investment Partners Reports 5% Stake In Co. As Of Oct. 14benzinga · 10/15/2026
- Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Yahoo · 10/6/2026
- MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development OfficerYahoo · 9/23/2026
- MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/11/2026
Insider Activity
Insider Actions →- John Joseph Johnston · June 17, 2026 · Grant49.6K
- John Joseph Johnston · June 17, 2026 · Grant30.4K
- Rekha Hemrajani · June 17, 2026 · Grant49.6K
- Rekha Hemrajani · June 17, 2026 · Grant30.4K
- Stanley C. Erck · June 17, 2026 · Grant49.6K
- Stanley C. Erck · June 17, 2026 · Grant30.4K
- Cynthia Collins · June 17, 2026 · Grant49.6K
- Cynthia Collins · June 17, 2026 · Grant30.4K
- William W. Brooke · June 17, 2026 · Grant49.6K
- William W. Brooke · June 17, 2026 · Grant30.4K
- Yasir B. Al-Wakeel · June 17, 2026 · Grant49.6K
- Yasir B. Al-Wakeel · June 17, 2026 · Grant30.4K
- Patrick J. Balthrop · June 17, 2026 · Grant49.6K
- Patrick J. Balthrop · June 17, 2026 · Grant30.4K
- Richard Douglas · June 17, 2026 · Grant49.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 63.57M
- Total value held
- $44.65M
- Institutional holders
- 126
- Unknown8.80M
- Unknown8.20M
- Unknown5.04M
- Unknown3.98M
- Unknown3.69M
- Unknown3.37M
- Unknown2.77M
- Unknown2.36M
- Unknown2.19M
- Unknown2.19M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer
MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.